# IDEAYA Biosciences Gains Buy Rating on Potential Standard-of-Care Melanoma Treatment

- URL: https://stocks.freetheai.org/news/ideaya-biosciences-gains-buy-rating-on-potential-standard-of-care-melanoma-1f0f8a
- Published: 2026-10-14T16:53:31Z
- Category: analyst_ratings; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:IDYA](https://stocks.freetheai.org/symbols/NASDAQ-IDYA), [NYSE:PFE](https://stocks.freetheai.org/symbols/NYSE-PFE), [NASDAQ:AMGN](https://stocks.freetheai.org/symbols/NASDAQ-AMGN)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Stifel resumed coverage on IDEAYA Biosciences (NASDAQ:IDYA) with a Buy rating and set a price target of $48, representing roughly 40% upside from its October 13 closing price. The investment firm highlighted the company's experimental combination therapy of darovasertib and crizotinib for first-line metastatic uveal melanoma, noting it has potential to become a primary standard of care.

Crizotinib, marketed by Pfizer Inc. (NYSE:PFE) as Xalkori for lung cancer, is being evaluated alongside darovasertib in collaborative trials with IDEAYA. Approval for the combination therapy is modeled for late Q2 2027, with long-term worldwide revenue projected to reach approximately $1.42 billion by 2035.

Investors should also keep an eye on IDE849, an antibody-drug candidate targeting small cell lung cancer. The asset is scheduled to advance into Phase 3 trials by the end of the year for patients whose disease progressed following treatment with Amgen Inc.'s (NASDAQ:AMGN) Imdelltra. Worldwide sales for IDE849 are projected to reach $643 million by 2035.

## Key points

- Stifel resumed coverage on IDEAYA Biosciences (NASDAQ:IDYA) with a Buy rating and a $48 price target.
- Analysts model a potential late Q2 2027 approval for the company's combination treatment in metastatic uveal melanoma.
- IDEAYA is collaborating with Pfizer Inc. (NYSE:PFE) on trials combining darovasertib with Pfizer's Xalkori.
- The combination therapy is projected to generate around $1.42 billion in global sales by 2035.
- IDEAYA plans to initiate a Phase 3 trial for its lung cancer drug IDE849 by the end of the year.

## Questions and answers

### What is Stifel's price target for IDEAYA Biosciences?

Stifel set a price target of $48 for IDEAYA Biosciences (NASDAQ:IDYA), representing approximately 40% upside based on the stock's October 13 closing price.

### What is IDEAYA Biosciences' key drug combination for eye cancer?

IDEAYA is testing a combination of darovasertib and Pfizer's crizotinib (Xalkori) as a potential standard-of-care treatment for first-line metastatic uveal melanoma.

### When could IDEAYA's combination treatment receive approval?

Analysts model a potential approval for the darovasertib and crizotinib combination in late Q2 2027.